Evaluation of new commercial enzyme-linked immunosorbent assay kits in the laboratory diagnosis of antiphospholipid syndrome in view of the revised classification criteria of the antiphospholipid syndrome

Blood Coagulation and Fibrinolysis

Volumn 17, Issue 8, 2006, Pages 651-659

  Devreese, Katrien M J ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Anti 2 glycoprotein I antibodies; Antiphospholipid antibodies; Antiphospholipid syndrome; Antiprothrombin antibodies; Lupus anticoagulants

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; IMMUNOASSAY; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCREENING TEST;

ANTIBODIES, ANTICARDIOLIPIN; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; ENZYME-LINKED IMMUNOSORBENT ASSAY; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LUPUS COAGULATION INHIBITOR; PROTHROMBIN;

EID: 33751062688     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000252600.09777.2b     Document Type: Article

References (38)

1. Galli M, Comfurius P, Maassen C, Hemker MC, de Baets MH, van Breda-Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to serum protein cofactor. Lancet 1990; 335:1544-1547.
2. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336:177-178.
3. de Groot PG, Derksen RHWM. Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost 2005; 3:1854-1860.
4. de Groot PG, Derksen RHWM. The antiphospholipid syndrome: clinical characteristics, laboratory features and pathogenesis. Curr Opin Infect Dis 2005; 18:205-210.
5. Arnout J. Antiphopholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost 2001; 86:83-91.
6. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101:1827-1832.
7. Zoghlami-Rintelen C, Vormittag R, Sailor T, Lehr S, Quehenberger P, Rumpold H, et al. The presence of IgG antibodies against beta-2-glycoprotein I predicts the risk of thrombosis in patients with lupus anticoagulant. J Thromb Haemost 2005; 3:1160-1165.
8. 2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104:3598-3602.
9. 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105:1540-1545.
10. 2- glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphopholipid syndrome. Blood 2003; 102:2717-2723.
11. 2-glycoprotein I and prothrombine, and risk of thrombosis. J Thromb Haemost 2005; 3:1231-1238.
12. de Groot PG, Lutters B, Derksen RHWM, Lisman T, Meijers JCM, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost 2005; 3:1993-1997.
13. Harris EN, Gharavi AE, Patel SP, Hughes GRV. Evaluation of the anticardiolipin antibody test: report of an international workshop held April 4 1986. Clin Exp Immunol 1987; 68:215-222.
14. Pierangeli SS, Stewart M, Silva LK, Harris EN. Report of an anticardiolipin wet workshop during the VIIth International Symposium on antiphospholipid antibodies. J Rheumatol 1998; 25:156-162.
15. Tincani A, Allegri F, Balestrieri G, Reber G, Sanmarco M, Meroni P, Boffa MC. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res 2004; 114:553-558.
16. Wong RCW, on behalf of the Australian aCL Working Party. Consensus guidelines for anticardiolipin antibody testing. Thromb Res 2004; 114:559-571.
17. 2-glycoprotein I antibodies. Standardization Group of the European Forum on Antiphopholipid Antibodies. J Thromb Haemost 2004; 2:1860-1862.
18. 2-glycoprotein I antibodies measurement by commercial assays. Thromb Haemost 2005; 94:665-672.
19. Wilson WA, Gharavi AE, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999; 42:1309-1311.
20. Arnout J. ISTH Scientific Standardisation Subcommitte lupus anticoagulants/phospholipid dependent antibodies. Boston, MA: International Society of Thrombosis and Haemostasis; 2000.
21. Nash MJ, Camilleri RS, Kunka S, Mackie IJ, Machin SJ, Cohen H. The anticardiolipin assay is required for senstive screening for antiphospholipid antibodies. J Thromb Haemost 2004; 2:1077-1081.
22. Nash MJ, Camilleri RS, Kunka S, Mackie IJ, Machin SJ, Cohen H. The anticardiolipin assay is required for senstive screening for antiphospholipid antibodies. J Thromb Haemost 2004; 2:1077-1081.
23. 2-glycoprotein I antibodies - when and how should they be measured? Thromb Res 2004; 114:527-531.
24. 2-glycoprotein I antibody provide additional information in patients with thrombosis? Thromb Res 2003; 111:29-32.
25. 2-glycoprotein I, the playmaker of the antiphospholipid syndrome. Clin Immunol 2004; 112:161-168.
26. De Moerloose P, Reber G. Antiphospholipid antibodies: do we still need to perform anticardiolipin ELISA assays? J Thromb Haemost 2004; 2:1071-1073.
27. Meroni PL, Tincani A. Should our approach to the anticardiolipin assay change 20 years after its discovery? J Thromb Haemost 2004; 2:1074-1076.
28. Miyakis S, Lockshin MD, Atsumi D, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4:295-306.
29. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74:1185-1190.
30. Devreese K. Interpretation of normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulants. Thromb Res 2006; in press.
31. Arnout J, Vanrusselt M, Huybrechts E, Vermylen J. Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin. Br J Haematol 1994; 87:94-99.
32. Greaves M, Cohen H, Machin SJ, Mackie I, on behalf of the Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000; 109:704-715.
33. Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost 2001; 86:83-91.
34. De Groot PG, Derksen HWM. The importance of measuring anticardiolipin antibodies. J Thromb Haemost 2006; 4:41-43.
35. Pierangeli SS, Harris EN. Clinical laboratory testing for the antiphospholipid syndrome. Clin Chim Acta 2005; 357:17-35.
36. Atsumi T, Ieko M, Bertolaccini ML, Ichikawa K, Tsutsumi A, Matsuura E, Koike T. Association of autoantibodies against the phophatidylserine-prothrombin complex with manifestations of the antiphopholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000; 43:1982-1993.
37. Ebeling F, Pettersson T, Muukhoven L, Vahtera E, Rasi V. Beta-2-glycoprotein I antibodies in patients with thrombosis. Scand J Clin Lab Invest 2003; 63:111-118.
38. Ichikawa K, Tsutsumi A, Atsumi T, Matsuura E, Kobayashi S, Hughes GRV, et al. A chimeric antibody with the human gamma 1 constant region as a putative standard for assays to detect IgG Beta-2-glycoprotein I antibodies. Arthritis Rheum 1999; 42:2461-2470.